By designing proteins de novo scientists can more efficiently create novel therapeutics tailored for specific biological ...

Eli Lilly has agreed to acquire Verve Therapeutics for up to $1.3 billion in a deal designed to bolster the buyer’s cardiovascular treatment pipeline with Verve’s gene editing therapies, led by ...

A Roots Analysis study showed the market for ADC manufacturing is $1.79 billion today, but is expected to grow to $7 billion ...

Advances are occurring in spectroscopy, reducing the challenges of rapid signal saturation and the need for extensive sample prep.

The AI unicorn's Perturb-seq atlas is publicly available and detects dose-dependent genetic effects to enhance predictive power for drug discovery.

In addition to being faster and less invasive than a traditional tissue biopsy, the blood test is also potentially more accurate.

PRDX6 and GSTP1 identified as promising enzyme targets for neuroblastoma, offering an alternative to retinoic acid differentiation therapy.